• Asian-Australasian Journal of Animal Sciences
• /
• v.18 no.2
• /
• pp.241-248
• /
• 2005

This study is aimed at understanding the role of arsenic in Roxarsone in causing fatty livers in mule ducks. One hundred 10-week-old mule ducks were randomly divided into 5 groups. Ducks received 2 weeks of various treatments followed by 2 weeks of withdrawal. The treatments were non-treatment (control), 300 mg/kg Roxarsone inclusion for 2 weeks ($1^{st}$ and $2^{nd}$ week), Roxarsone inclusion for one week ($2^{nd}$ week only), restrict feeding, or Roxarsone analogue (3-nitro-4-hydroxyphenyl acid) inclusion. Results showed that feed intake and body weight in the Roxarsone groups and the restrict feeding group decreased significantly during the treatment period. However only the liver and heart weights were significantly decreased (p<0.05) in the restrict feeding group. Fatty acid synthetase (FAS) activity showed a significant decrease (p<0.05) in the Roxarsone groups and the restrict feeding group, two-week-Roxarsone treatment significantly increased NADP-malic dehydrogenase (MDH) activity compared to the restrict (p<0.05). After 2 weeks drug withdrawal, the 1-week-Roxarsone or restrict feeding group showed significantly increased (p<0.05) glucose-6-phosphate dehydrogenase (G-6-PDH) activity (p<0.05). Two-week-Roxarsone treatment significantly decreased (p<0.05) the high density lipoprotein (HDL) and increased (p<0.05) the low density lipoprotein (LDL) and very low density lipoprotein (VLDL) ratio. After drug withdrawal, the 1-week-Roxarsone or restrict feeding group showed significantly increased (p<0.05) creatine kinase (CK) activity. The 2-week-Roxarsone treatment group showed significantly increased (p<0.05) aspartate aminotransferase (AST) activity. The restrict feeding treatment group showed significantly decreased (p<0.05) total protein (TP) concentration. After drug withdrawal, the related enzyme activities in the blood that reflected the liver function were restored to the normal physiological range, except for the total bilirubin concentration and CK activity in the 1-week-Roxarsone group. This group showed a significant increase (p<0.05). Thus, the reasons for liver enlargement in the Roxarsone and restrict feeding groups were different.

• Asian-Australasian Journal of Animal Sciences
• /
• v.19 no.3
• /
• pp.412-417
• /
• 2006

This study evaluated the effectiveness of different arsenical sources on inducing fatty liver, on changes in lipid metabolism and on liver function in mule ducks. Sixty twelve-week-old mule ducks were selected and randomly divided into five treatments, including the control group and four different arsenical sources; Roxarsone (300 mg/kg), arsanilic acid, $As_2O_5$ or $As_2O_3$, containing 85.2 mg/kg arsenic were included in the basal diet. The ducks were fed the medicated basal diet for 3 weeks followed by a one-week drug withdrawal. The results showed Roxarsone treatment decreased body weight, feed intake, liver weight and abdominal fat weight (p<0.05), while it increased the relative liver weight (p<0.05) during medication period ($3^{rd}$ week). The $As_2O_5$ treatment decreased abdominal fat weight and relative abdominal fat weight when compared to the control (p<0.05). Only Roxarsone among the treatment groups increased feed intake, liver weight and relative liver weight, while the $As_2O_3$ group showed the lightest liver weight and relative liver weight among treatment groups during the withdrawal period ($4^{th}$ week). The Roxarsone group decreased (p<0.05) NADP-malic dehydrogenase (MDH) and acetyl-CoA carboxylase (ACC) activities and increased (p<0.05) cholesterol concentration during the medication period, and elevated the MDH and ACC activities during the withdrawal period. All four arsenical treatment groups showed lymphocytic infiltration in liver tissue, while the Roxarsone and $As_2O_3$ treatments showed an increase in aspartate aminotransferase (AST) and lactate dehydrogenase (LDH) activities (p<0.05). During the withdrawal period, arsenical treatments resulted in liver vacuoles. However, the arsenicals differed in effectiveness and mechanisms of inducing fat vacuoles.

• Asian-Australasian Journal of Animal Sciences
• /
• v.19 no.1
• /
• pp.48-54
• /
• 2006

Roxarsone (3-nitro-4-hydroxyphenylarsonic acid) has been used as feed additives in poultry industries to improve production and control coccidiosis. The effect of high dietary levels of Roxarsone (ROX) on the performance and function of internal organs and the kinetics of recovery as well as its after-effects were examined in laying hens. The inclusion rates of ROX were 0, 100, 200, 300, and 400 mg per kg feed. Inclusion up to 200 mg did not show any adverse effects (p>0.05), whereas in the 300 and 400 mg groups, significant effects, particularly in the latter, were observed for three weeks after ROX addition (p<0.05). Recovery of the physical appearance occurred soon after ROX addition was withdrawn. Recovery of performance and internal organs, however, appeared to be dependent on the amount of residual ROX in the body; as the amount of ROX decreased, the toxic effect of ROX also decreased. In the third week after the withdrawal of ROX, complete recovery was observed in the lower dosage groups (100 or 200 mg groups) (p>0.05), whereas in the higher dosage groups (300 or 400 mg groups), recovery took at least five weeks; when complete recovery was observed in egg production and in liver weight (p>0.05). On the other hand, ROX might have damaged the liver and other tissues. The recovery of liver weight was probably due to accumulation of fatty particles rather than repair. It appeared, therefore, there were little after-effects of ROX on the hen's physical appearance, but some internal organs were probably damaged.

• Journal of Korean Society of Environmental Engineers
• /
• v.32 no.6
• /
• pp.631-638
• /
• 2010

The objective of this study was to evaluate the efficiency of zerovalent iron and basic oxygen furnace slag on arsenic stabilization in soils. For this, arsenic (V) contaminated soil and roxarsone contaminated soil were incubated after incorporation with zerovalent iron (ZVI) or basic oxygen furnace slage (BOFS) at four different levels (0%, 1%, 3%, and 5%) for 30 days and then the residual concentrations of arsenic were analysed following extraction with aqua reqia, 1N HCl and 0.01 M $CaCl_2$. The total concentration of arsenic was 2,285 mg/kg in the As(V) contaminated soil and 6.5 mg/kg in the roxarsone contaminated soil. 1 N HCl extractable arsenic concentration in the As(V) contaminated soil was initially 1,351 mg/kg and this was significantly declined by 713~1,034 mg/kg following incubation with ZVI while BOFS treatment showed no effect on the stabilization of inorganic arsenate except 5% treatment which showed around 100 mg/kg reduction in 1N HCl extractable arsenic. Similarly, in the roxarsone contaminated soil 1N HCl extractable concentration of arsenic was reduced from 3.13 mg/kg to 0.69 mg/kg with ZVI treatment increased from 1% to 5% while BOFS treatment did not lead to any statistically significant reduction. Available (0.01M $CaCl_2$ extractable) arsenic was initially 0.85 mg/kg in the As(V) contaminated soil and this declined by 0.79 mg/kg following incorporation with 5% ZVI, which accounted for more than 90% of the available As in the control. When As(V)-contaminated soil was treated with BOFS, the available arsenic was increased due to competing effect of the phosphate originated from BOFS with arsenate for the adsorption sites. For the roxarsone contaminated soil, the greater the treatment of ZVI or BOFS, the lower the available arsenic concentration although it was still higher than that of the control.

• Asian-Australasian Journal of Animal Sciences
• /
• v.25 no.3
• /
• pp.382-392
• /
• 2012

This study evaluated the effects of dietary anticoccidial drugs plus antibiotic growth promoters (AGPs) on parameters of immunity in commercial broiler chickens. Day-old chicks were raised on used litter from a farm with endemic gangrenous dermatitis to simulate natural pathogen exposure and provided with diets containing decoquinate (DECX) or monensin (COBN) as anticoccidials plus bacitracin methylene disalicylate and roxarsone as AGPs. As a negative control, the chickens were fed with a non-supplemented diet. Immune parameters examined were concanavalin A (ConA)-stimulated spleen cell proliferation, intestine intraepithelial lymphocyte (IEL) and spleen cell subpopulations, and cytokine/chemokine mRNA levels in IELs and spleen cells. ConA-induced proliferation was decreased at 14 d post-hatch in DECX-treated chickens, and increased at 25 and 43 d in COBN-treated animals, compared with untreated controls. In DECX-treated birds, increased percentages of $MHC2^+$ and $CD4^+$ IELS were detected at 14 d, but decreased percentages of these cells were seen at 43 d, compared with untreated controls, while increased $TCR2^+$ IELs were evident at the latter time. Dietary COBN was associated with decreased fractions of $MHC2^+$ and $CD4^+$ IELs and reduced percentages of $MHC2^+$, $BU1^+$, and $TCR1^+$ spleen cells compared with controls. The levels of transcripts for interleukin-4 (IL-4), IL-6, IL-17F, IL-13, CXCLi2, interferon-${\gamma}$ (IFN-${\gamma}$), and transforming growth factor${\beta}$4 were elevated in IELs, and those for IL-13, IL-17D, CXCLi2, and IFN-${\gamma}$ were increased in spleen cells, of DECX- and/or COBN-treated chickens compared with untreated controls. By contrast, IL-2 and IL-12 mRNAs in IELs, and IL-4, IL-12, and IL-17F transcripts in spleen cells, were decreased in DECX- and/or COBN-treated chickens compared with controls. These results suggest that DECX or COBN, in combination with bacitracin and roxarsone, modulate the development of the chicken post-hatch immune system.